JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on June 15, 2007; DOI: 10.1124/jpet.107.124958


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.107.124958v1
322/3/1286    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lindstrom, E.
Right arrow Articles by Vauquelin, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lindstrom, E.
Right arrow Articles by Vauquelin, G.


Received for publication May 3, 2007.
Revised June 14, 2007.
Accepted for publication June 14, 2007.

Neurokinin (NK)1 receptor antagonists: Correlation between in vitro receptor interaction and in vivo efficacy

Erik Lindstrom 1, Bengt von Mentzer 2*, Ingrid Pahlman 3, Ingela Ahlstedt 2, Anna Uvebrant 3, Elin Kristensson 1, Rakel Martinsson 4, Anna Noven 3, Jennie de Verdier 3, Georges Vauquelin 5

1 Integrative Pharmacology 2 Molecular Pharmacology 3 DMPK 4 Integrativ Pharmacology 5 Molecular and Biochemical Pharmacology

* Address correspondence to: E-mail: bengt.mentzer{at}astrazeneca.com

Abstract

We compared the neurokinin 1 receptor (NK1R) antagonists aprepitant, CP99,994 and ZD6021 with respect to receptor interactions and duration of efficacy in vivo. In Ca2+ mobilization assays (FLIPR), antagonists were applied to human U373MG cells simultaneously with or 2.5 min before substance P (SP). In reversibility studies, antagonists were present for 30 min before washing and responses to SP were repeatedly measured afterwards. The compounds were administered i.p. to gerbils and the gerbil foot tap (GFT) response was monitored at various time points. The NK1R receptor occupancy for aprepitant was determined in striatal regions. Levels of compound in brain and plasma were measured. Antagonists were equipotent at human NK1R and acted competitively with SP. After pre-incubation, aprepitant and ZD6021 attenuated the maximal responses, while CP99,994 only shifted the SP concentration-response curve to the right. The inhibitory effect of CP99,994 was over within 30 min while for ZD6021, 50% inhibition still persisted after 60 min. Aprepitant produced maximal inhibition lasting at least 60 min. CP99,994 (3 µmol/kg) inhibited GFT by 100% 15 min after administration but the effect declined rapidly together with brain levels thereafter. The efficacy of ZD6021 (10 µmol/kg) lasted 4h and correlated well with brain levels. Aprepitant (3 µmol/kg) inhibited GFT and occupied striatal NK1R by 100% for >48h despite brain levels of compound were below the limit of detection after 24h. Slow functional reversibility is associated with long-lasting in vivo efficacy of NK1R antagonists while the efficacy of compounds with rapid reversibility is reflected by their pharmacokinetics.


Key words: Insurmountable, Neurokinin 1 receptors, competitive, gerbil foot tap, long-lasting effect, reversibility


This article has been cited by other articles:


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. Xu, F. Xu, and E. Barrett
Metalloelastase in lungs and alveolar macrophages is modulated by extracellular substance P in mice
Am J Physiol Lung Cell Mol Physiol, July 1, 2008; 295(1): L162 - L170.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.